HOME > BUSINESS
BUSINESS
- Sumitomo Dainippon, Taiho to Invest US$30 Million Each in Remiges BioPharma Fund
July 25, 2014
- Ono, BMS Announce Strategic Alliance for 5 Immuno-Oncology Products
July 25, 2014
- R-Tech Ueno Files for Orphan Drug Designation for Unoprostone Isopropyl for Retinitis Pigmentosa
July 25, 2014
- With Series of Antidiabetics on the Way, Prioritization Will Be a Challenge: Lilly Japan Diabetes Head
July 25, 2014
- Astellas Gears Up to Accelerate R&D
July 24, 2014
- Maruho Seeks Approval of Antibacterial Drug Ozenoxacin in Japan
July 24, 2014
- Japan Antidepressant Market Valued at 151 Billion Yen in 2022
July 24, 2014
- Jiangsu Hengrui Medicine of China Establishes Japanese Subsidiary; Aims for Sales of 10 Billion Yen by 2022
July 24, 2014
- Takeda, ASKA to Cease Seltouch Marketing by Late September
July 24, 2014
- Kyorin Licenses OAB Treatment Vibegron from Merck
July 24, 2014
- Research Lab for High-Value Generics Goes Live: Kobayashi Kako
July 23, 2014
- Terumo US Unit Opens New Plant in Vietnam
July 23, 2014
- Tatsumi Kagaku Adjusts Supply of Nu-lotan Generic
July 22, 2014
- Disclosure of Payments from Drug Makers to Doctors Delayed
July 22, 2014
- Chugai Obtains Marketing Rights for Antiemetic NEPA in the UK, Ireland from Helsinn Group
July 22, 2014
- Ethical Drug Sales Down 6.5% in May: Crecon Report
July 18, 2014
- Novartis, Maruho Form Sales Tie-Up for Psoriasis Agent
July 18, 2014
- Carna Shooting for 1st Licensing Deal on Kinase Inhibitor in 2014
July 18, 2014
- Ono to Target Cancers with Unmet Medical Needs: President
July 18, 2014
- AnGes MG Initiates Development of Next Generation Collategene
July 18, 2014
ページ
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…